Treatment with mesenchymal stem cells targets angiogenic imbalance in chronic liver disease
Célula-tronco mesenquimal (MSC) therapy shows promise in treating chronic liver disease by addressing angiogenic imbalance. This article analyzes the mechanism of MSCs in restoring vascular equilibrium and improving liver function. Learn about the potential of MSCs for CLD treatment.



